Paras Sharma @paras_biotech Twitter profile

Last Seen Profiles

@z_orkin

@Motorsport

@athulrajathul4

@RFAArgus

@AdmireRegions

@camaleonzio

@tailopez

@GarimeSacha

@utodj

@eMLS

@un_mauvais

@xksaa11

@rainha_geo

@xDaily

@gusfardas

@KristinaLi27289

@PatoNy22

@mlbbfess

@STAGESQUARE

@stwgemoy

@BOKEPBOCILVIRA3

@remotejoby

@ESaporita99951

@Bengha4

@Fumanjini

@Bill_Gross

@ScarMestevez

@wywomuzysuv

@72hrs

@pili99p

@GeorgeMasonU

@Etytaaaa

@lahislopez9

@souta5375

@jandakembangstw

@Pisisavar

Paras Sharma

@paras_biotech

1 year

Cancer Chemotherapy Snapshot -

10

229

716

Paras Sharma

@paras_biotech

2 years

Cell therapy Landscape -

6

75

548

Paras Sharma

@paras_biotech

2 years

Summary of Gene Editing BD deals large pharma/biotech companies have engaged primarily in collaborations with innovative CRISPR companies to access the technology

4

114

532

Paras Sharma

@paras_biotech

2 years

Top 10 drugs over time (end-user sales) (2007-2027)

12

109

511

Paras Sharma

@paras_biotech

14 days

Biotech M&A 2023/24: Acquirer's interest in Ph2 stage assets From Cantor

6

36

198

Paras Sharma

@paras_biotech

2 years

Disruptive Innovation takes time to inflect (as presented by mAb dev path)

6

66

357

Paras Sharma

@paras_biotech

3 years

Biotech IPOs by disease type (2012-2021)

15

79

348

Paras Sharma

@paras_biotech

2 years

Clinical trials success rate by disease area (2010-2020) **Look at Hem rate of success from Ph2-Ph3: 48% while Oncology is at 25%

5

82

346

Paras Sharma

@paras_biotech

2 years

Companies developing iPSC-based cell therapies

10

53

300

Paras Sharma

@paras_biotech

2 years

Oligo/RNA Therapeutics Landscape *15 are approved to date & 267 in the clinic (totaling sales of $3.5B in 2021 excluding covid vaccine)

7

47

297

Paras Sharma

@paras_biotech

9 months

How competitive recent Biotech M&A deals were? **Prometheus had 15 parties in the Data room Source: Cantor

15

47

273

Paras Sharma

@paras_biotech

2 years

Who got the tools (gene editing)

7

52

279

Paras Sharma

@paras_biotech

2 months

RadioPharma Summary from Oppenheimer *38 companies and 45 clinical stage programs, including: 8 Phase III; 9 Phase II; and 28 Phase I/II programs

5

63

274

Paras Sharma

@paras_biotech

2 years

Big Pharma's collab with protein degrader focused companies

4

46

260

Paras Sharma

@paras_biotech

2 years

Most competitive gene-therapy indications **mapped out from ~800 disclosed programs, including ~200 clinical stage, from over 170 companies From Evercore

11

47

258

Paras Sharma

@paras_biotech

2 years

List of T-Cell Engaging Bispecifics in Solid Tumors Source: WB

6

47

246

Paras Sharma

@paras_biotech

3 years

Biopharma/MedTech Cash Runway Map Source: Leerink

7

38

230

Paras Sharma

@paras_biotech

7 months

Cowen's top 10 potential surprises of 2024 $XBI

12

39

222

Paras Sharma

@paras_biotech

3 years

Biotech Rx Collaborations 2022 across diff modalities Large pharma seeking access to early stage novel cells/tools/platforms w/ decent upfronts

7

44

221

Paras Sharma

@paras_biotech

2 years

Failed PD-(L)1 Inhibitor trials across tumor types

7

35

218

Paras Sharma

@paras_biotech

2 years

How many months it takes to recruit patients across different therapeutic area ? Source: Cowen

10

46

219

Paras Sharma

@paras_biotech

2 years

Potential acquisition targets & main value driver

17

40

212

Paras Sharma

@paras_biotech

3 months

12 gene therapies across 10 indications have been approved by the FDA to date generating $2B/yr **there are 677 gene therapy/editing prgms being developed across 210 companies Source: William Blair

7

39

210

Paras Sharma

@paras_biotech

11 months

Origin of Key BioPharma Drugs: - BMS all through acquisition - Novo all in-house

11

28

204

Paras Sharma

@paras_biotech

3 years

Good summary - Status of the biotech industry by Evercore's Josh Schimmer

7

29

188

Paras Sharma

@paras_biotech

8 months

Cell Therapy's side-hustle: fixing autoimmunity

8

43

190

Paras Sharma

@paras_biotech

5 months

Top 20 Drug Class Leaders by 2028 Source: Cowen

4

40

189

Paras Sharma

@paras_biotech

2 years

Benchmarking efficacy for approved Auto CAR-Ts From Guggenheim

9

48

189

Paras Sharma

@paras_biotech

2 years

Of the 25 U.S./E.U. approved Cell/Gene/RNA therapies, 2021 WW combined sales totaled $6.48B

9

27

190

Paras Sharma

@paras_biotech

2 years

2020-2022 YTD Biotech M&A: in terms of modality, stage of dev & premium

5

31

187

Paras Sharma

@paras_biotech

2 years

For those who are interested in targeted protein degraders (PROTACs & MGDs etc.) - Some well-validated but historically poorly tractable targets in the space (w/ 35 pureplay biotechs) Source: Guggenheim

2

32

180

Paras Sharma

@paras_biotech

2 years

Biopharma Industry Growth by Drug Modality (2017-2026)

8

40

182

Paras Sharma

@paras_biotech

2 years

Top 20 academic centers ranked by number of issued biotech patents Only 1 non-US institute !

9

37

181

Paras Sharma

@paras_biotech

2 years

JPM's good summary on potential impact of Democrats’ Inflation Reduction Act on Pharma

4

35

178

Paras Sharma

@paras_biotech

2 years

List of approved Gene Therapies **best selling is ZOLGENSMA w/ 2021 ~$1.4B Revs

6

40

171

Paras Sharma

@paras_biotech

2 years

Biopharma's company innovation & success rates

11

30

169

Paras Sharma

@paras_biotech

2 years

Percent of Biotechs trading below cash (2002-2022) At a time when cost of capital is high - what's the value of cash when company burning cash at a crazy rate - the -ve EVs will turn positive quickly

3

37

166

Paras Sharma

@paras_biotech

7 months

It has always been about the rates $XBI

6

35

164

Paras Sharma

@paras_biotech

8 months

As usual excellent report by Stifel: Why Invest in Biotech ? This one caught my eye -

5

18

160

Paras Sharma

@paras_biotech

3 years

Biotech IPOs by stage of the company

11

28

153

Paras Sharma

@paras_biotech

2 years

Excellent Snapshot of Q2 reporting by Large Pharma Source: WB

5

35

159

Paras Sharma

@paras_biotech

2 years

Revenues by Cell and Gene Therapy products (2018-2021) Zolgensma leading the pack !

3

27

159

Paras Sharma

@paras_biotech

11 months

Excellent review by Sami Corwin at William Blair on In-Vivo CAR-T Landscape

5

27

151

Paras Sharma

@paras_biotech

2 years

Thematic-Biotech performance in 2022

5

26

146

Paras Sharma

@paras_biotech

3 months

NK-cell Targeting Therapies Landscape Source: WB

5

31

148

Paras Sharma

@paras_biotech

3 years

2021YTD Biotech IPO Scorecard Source: Jefferies

4

24

147

Paras Sharma

@paras_biotech

2 years

Gene Thx Public/Pvt competitive landscape

3

28

144

Paras Sharma

@paras_biotech

1 year

Squamous cell lung cancer: Current landscape and future therapeutic options

0

39

143

Paras Sharma

@paras_biotech

2 years

Biotech sector need some good clinical outcomes 2Q 2022 Ph3 & Ph2 readouts

6

23

141

Paras Sharma

@paras_biotech

10 months

41 Biopharmas exploring strategic options Source: Stifel

10

24

140

Paras Sharma

@paras_biotech

6 months

List of AI based Biotechs raised investments (74 companies) **Most raised >$100M - wonder how many have assets in the clinic with poc in patients Source: Guggenheim

14

21

138

Paras Sharma

@paras_biotech

3 years

Who's trading near cash ...and who's burning cash? w/ <100M mkt cap biotechs

16

21

133

Paras Sharma

@paras_biotech

1 year

Biotech: LONG The Launch ? Appreciation since drug approvals

11

16

135

Paras Sharma

@paras_biotech

1 year

Baker Brothers $1B -> $9B (in 21 yrs) in SGEN exit

4

10

134

Paras Sharma

@paras_biotech

2 years

R&D – Waves of Innovation vs. Structural Change Source: CS

3

20

137

Paras Sharma

@paras_biotech

2 years

Biotech IPO from 2011-2022 YTD *dropped the ball Source: Oppenheimer

6

30

133

Paras Sharma

@paras_biotech

1 year

GLP-1s racing towards $100B revs

4

24

131

Paras Sharma

@paras_biotech

2 years

Excellent analysis "Biotech needs Pharma - But Pharma needs Biotech too" **1/2 of the ‘top 5’ pdts were developed organically, 30% acquired & 20% in-licensed mainly from small biotechs Source: Schimmer (Evercore)

5

31

131

Paras Sharma

@paras_biotech

4 months

VC Fund size to DPI plot - 168 funds covered & Vintage year 2014-2016 1. Only ~20% are in the carry 2. >$2B barely returned deployed capital back to LPs (not including fees/hurdle) 3. Median fund size of $200M returned >1.5x DPI Will post other thematic observations later

7

26

110

Paras Sharma

@paras_biotech

1 month

8 Approved AAV Gene Therapies **Elevidys just received label expansion to include all DMD patients ages 4 and older From William Blair

3

41

128

Paras Sharma

@paras_biotech

1 year

Pipeline herding in drug development - In 2000, there were on avg 3 assets/target In 2022, there are on avg 7 assets/target (in oncology its 9 assets/target)

3

29

126

Paras Sharma

@paras_biotech

4 months

World of ADC: PFE is ahead however NVS, Lilly, Gilead, JNJ and Amgen lagging behind. Graph From Guggenheim

2

31

121

Paras Sharma

@paras_biotech

3 months

Radiopharma: ~25 unique targets being pursued.. **Past 12 months alone there have been 4 major acq of Biotech companies totaling ~$8.6Bn in value, equaling the total value of all radiopharma acq in ~10 years (~$8.9Bn)

3

28

122

Paras Sharma

@paras_biotech

9 months

Radiopharma: Targets Under Investigation Source: William Blair

5

20

122

Paras Sharma

@paras_biotech

1 year

Have seen diff. interpretation of pharma's evolution Below is from torreya -

2

28

122

Paras Sharma

@paras_biotech

10 months

Stifel's #ESMO23 snapshot

3

23

123

Paras Sharma

@paras_biotech

21 days

Chart of the week: The Biopharma social contract From HSBC

0

20

123

Paras Sharma

@paras_biotech

2 years

There you go: most negative EV biotech companies ** These held ~$14B net cash at end of 1Q22, w/ cumulative mkt cap of ~$8B Source: Evercore

6

23

120

Paras Sharma

@paras_biotech

2 months

Stifel's ASCO Summary **Statnews - "This was a big meeting for small hazard ratios. We’re talking “HRs” in the teens from targeted medicines made by AstraZeneca and Pfizer"

1

28

123

Paras Sharma

@paras_biotech

2 years

Mapping Biopharma's "Open Innovation" approach

2

24

118

Paras Sharma

@paras_biotech

27 days

Obesity Comp - in a single graph (from 340 pgs long Obesity report by Stifel)

4

23

123

Paras Sharma

@paras_biotech

2 years

Therapeutic Biotech Research Collaborations in 2023 Source: William Blair

2

19

121

Paras Sharma

@paras_biotech

1 year

Targeted Protein Degradation: has seen early clinical de-risking data for several TPD programs, largely for validated targets that continue to prove out this modality's utility. However, there has yet to be a “wow” moment for the field Source: WF Current TPD Tech -

5

21

120

Paras Sharma

@paras_biotech

3 months

Leerink's Autologous Cell Therapy breakdown of cost by process step (CoGS per dose $269K) - beside labor, transduction/viral vector cost is the biggest component.

4

12

118

Paras Sharma

@paras_biotech

5 months

Lean Muscle Preservation Landscape: Beyond GLP-1s in Obesity Sources: Piper & Guggenheim (data to date/timelines)

3

18

113

Paras Sharma

@paras_biotech

2 years

With 8 Ph3 failures in 2022, IO-biotech in a protracted funk !

8

27

110

Paras Sharma

@paras_biotech

2 years

Cell Therapy Private Funding by Deal Size & No. **Avg deal size for 2021 ($95M) & 2022 ($102M)

5

23

104

Paras Sharma

@paras_biotech

1 year

ADCs in clinical dev by tumor type

2

21

110

Paras Sharma

@paras_biotech

2 years

The mighty 750% performance biotech club (Since 2000 IPOs)

6

15

108

Paras Sharma

@paras_biotech

6 months

Obesity Targets by Guggenheim

2

21

102

Paras Sharma

@paras_biotech

2 years

NASH is back - this time for good ?

4

20

105

Paras Sharma

@paras_biotech

1 year

By Lead Asset Therapeutic Area: % change in avg. Enterprise Value of Biotech (Dec 31, 2021 to June 30, 2023)

5

20

106

Paras Sharma

@paras_biotech

21 days

2024 YTD: Big Winners & Losers in Biotech From Cantor

2

14

106

Paras Sharma

@paras_biotech

2 years

There are 143 drugs in the current Alzheimer’s disease drug development pipeline *including 11 programs in Ph2 for Aβ thesis

4

26

105

Paras Sharma

@paras_biotech

1 year

Emerging biopharma companies originated 67% of all new drugs in 2022

1

23

105

Paras Sharma

@paras_biotech

2 years

The state of biotech in 2022: at the intersection of fear and opportunity SMBC's road show notes (as of 05/06)

3

12

104

Paras Sharma

@paras_biotech

1 year

mRNA Cancer Vaccines -

1

34

103

Paras Sharma

@paras_biotech

2 years

The 750%+ Performance Club *Since 2000, 17 companies have generated >750% upside since their IPO price

8

13

104

Paras Sharma

@paras_biotech

2 years

Q1 Biotech funding 1998-2022

10

32

104

Paras Sharma

@paras_biotech

2 years

Company heat map of sensitivity to Inflation Reduction Act healthcare reform

7

17

100

Paras Sharma

@paras_biotech

1 year

Upcoming oral GLP-1s milestones

8

19

103

Paras Sharma

@paras_biotech

2 years

Biotech: How we got here is Why we are here - these 2 charts combined tell an interesting story Overfunded + early stage exposure to generalists (2000s-2020s)